Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. (November 2018)

• Record Type: Journal Article
• Authors: Nazeri, Elahe; Gouran Savadkoohi, Mohammad; Majidzadeh-A, Keivan; Esmaeili, Rezvan
• Is Part Of: Critical reviews in oncology/hematology. Volume 131(2018)
• Page Start: 102
• Page End: 109
• Publication Date: 2018-11
• Subjects: Chondrosarcoma -- Chemotherapy -- Radiotherapy -- Drug resistance -- Targeted therapy -- Tumor microenvironment; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2018.09.001
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Sarcomas are known as a heterogeneous class of cancers arisen in the connective tissues and demonstrated various histological subtypes including both soft tissue and bone origin. Chondrosarcoma is one of the main types of bone sarcoma that shows a considerable deficiency in response to chemotherapy and radiotherapy. While conventional treatment based on surgery, chemo-and radiotherapy are used in this tumor, high rate of death especially among children and adolescents are reported. Due to high resistance to current conventional therapies in chondrosarcoma, there is an urgent requirement to recognize factors causing resistance and discover new strategies for optimal treatment. In the past decade, dysregulation of genes associated with tumor development and therapy resistance has been studied to find potential therapeutic targets to overcome resistance. In this review, clinical aspects of chondrosarcoma are summarized. Moreover, it gives a summary of gene dysregulation, mutation, histone modifications and non-coding RNAs associated with tumor development and therapeutic response modulation. Finally, the probable role of tumor microenvironment in chondrosarcoma drug resistance and targeted therapies as a promising molecular therapeutic approach are summarized.